Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
15 Jul 2019 7:00 am
RNS
Update on US regulatory decision for Farxiga
12 Jul 2019 7:00 am
RNS
Imfinzi granted US Orphan Drug Designation for
01 Jul 2019 3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Forxiga receives positive EU CHMP opinion for
  7:00 am
RNS
Fasenra receives positive EU CHMP opinion for self
27 Jun 2019 7:00 am
RNS
Imfinzi improves overall survival at interim
19 Jun 2019 7:00 am
RNS
Breztri Aerosphere (PT010) approved in Japan for
  7:00 am
RNS
Lynparza approved in Japan for 1st-line
  7:00 am
RNS
Bevespi Aerosphere approved by the Japanese
18 Jun 2019 7:00 am
RNS
Lynparza approved in the EU for 1st-line
17 Jun 2019 7:00 am
RNS
Calquence significantly prolonged the time patient
12 Jun 2019 4:45 pm
RNS
Publication of a Prospectus
06 Jun 2019 7:00 am
RNS
Calquence Phase III ELEVATE-TN trial met primary
05 Jun 2019 12:36 pm
EQS
AstraZeneca: Where has all the cash gone?
03 Jun 2019 3:00 pm
RNS
Block listing Interim Review
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Lynparza nearly doubled time patients lived with
10 May 2019 7:00 am
RNS
Pooled analyses of the roxadustat global Phase III
08 May 2019 2:00 pm
RNS
Director/PDMR Shareholding
  11:00 am
RNS
Director Declaration
  7:00 am
RNS
Trastuzumab deruxtecan demonstrated clinically
07 May 2019 7:00 am
RNS
Calquence PhIII ASCEND trial met primary endpoint
03 May 2019 7:00 am
RNS
Qternmet XR approved in the US for type-2 diabetes
01 May 2019 3:00 pm
RNS
Total Voting Rights
  12:00 pm
RNS
Director/PDMR Shareholding
29 Apr 2019 7:00 am
RNS
Lynparza receives positive EU CHMP opinion for 1st
26 Apr 2019 5:45 pm
RNS
Result of AGM
  7:00 am
RNS
AZN: Q1 2019 Results
10 Apr 2019 7:00 am
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 4:10 pm
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 1:30 pm
RNS
Holding(s) in Company
  1:30 pm
RNS
Holding(s) in Company
03 Apr 2019 10:00 am
RNS
Director/PDMR Shareholding
02 Apr 2019 3:00 pm
RNS
Total Voting Rights
01 Apr 2019 6:00 pm
RNS
Astrazeneca
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 5:15 pm
RNS
Results of Placing
  7:00 am
RNS
Proposed placing of new ordinary shares
  7:00 am
RNS
AZ and Daiichi Sankyo enter collaboration in novel
27 Mar 2019 7:00 am
RNS
Forxiga approved in Japan for type-1 diabetes
25 Mar 2019 7:00 am
RNS
Forxiga approved in Europe for type-1 diabetes
18 Mar 2019 7:00 am
RNS
US FDA grants saracatinib ODD for IPF
14 Mar 2019 12:00 pm
RNS
Notice of AGM
12 Mar 2019 12:00 pm
RNS
Director/PDMR Shareholding
06 Mar 2019 7:00 am
RNS
Filing of Form 20-F with SEC
05 Mar 2019 11:00 am
RNS
Annual Financial Report
04 Mar 2019 4:04 pm
RNS
Holding(s) in Company
  4:04 pm
RNS
Holding(s) in Company
01 Mar 2019 3:00 pm
RNS
Total Voting Rights
  1:45 pm
RNS
Lynparza receives positive EU CHMP opinion
26 Feb 2019 7:00 am
RNS
Lynparza significantly delayed disease progression
25 Feb 2019 7:00 am
RNS
Brilinta's PhIII THEMIS trial met primary endpoint
14 Feb 2019 7:00 am
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 7:00 am
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 7:05 am
RNS
US FDA grants Breakthrough Therapy Designation
  7:00 am
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 3:00 pm
RNS
Total Voting Rights
  1:17 pm
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 2:00 pm
RNS
Completion of divestment of US Synagis rights
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t